Resources
designed
for you
For adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD).
Expert perspectives
Experts walk you through the clinical trial programs that evaluated the efficacy and safety of ENTYVIO, discuss how they evaluate and select treatments for their patients, and provide examples of how they incorporate ENTYVIO into their practice.
Insurance coverage
Use our formulary lookup tool to find ENTYVIO insurance coverage information for patients in your area.
Scientific congresses
Get the most up-to-date information and expert perspectives about ENTYVIO at these scientific
congresses. We hope to see you there!
Downloadable resources
General resources for your practice
ENTYVIO Patient Brochure
Help your patients get to know ENTYVIO.
ENTYVIO Infusion Schedule
A calendar view of the ENTYVIO infusion schedule and infusion appointment preparation tips.
Full Prescribing Information
Includes the Medication Guide for ENTYVIO and IFU for ENTYVIO Pen.
EHR Resource Summary
Access guides intended to assist in configuring EHR/EMR systems to facilitate prescribing ENTYVIO Pen.
Patient Support Program Resources
Use these resources to help you, your staff, and your patients navigate the EntyvioConnect patient support program
Program Overview
Find out how EntyvioConnect can
support your patients throughout
the entire insurance approval
process.
Enrollment Guide
Learn how to enroll your patients in
EntyvioConnect and access its full
range of programs and services.
Practice Manager Support
Matrix
A helpful guide for practice
managers about how to utilize
EntyvioConnect resources to
support patients.
Co-pay Reimbursement Instructions
A guide for patients about how they may be able to lower their out-of-pocket costs for ENTYVIO.
Looking for more resources related to insurance support, financial assistance, and reimbursement?
COVID-19 information
Patient safety is Takeda’s top priority
We understand those living with moderate to severe ulcerative colitis and Crohn's disease and their loved ones may be facing a high level of uncertainty during this serious health situation.
For additional information on COVID-19, please visit www.takeda.com.
Explore more topics
Get in touch with an ENTYVIO Clinical Sales Specialist
Need to refer a patient to an infusion center?
The content on this page has been written and
reviewed by Takeda.
IMPORTANT SAFETY INFORMATION
Contraindications
ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
WARNINGS AND PRECAUTIONS
- Infusion-Related and Hypersensitivity Reactions: Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart
IMPORTANT SAFETY INFORMATION
Contraindications
ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
Warnings and precautions
- Infusion-Related and Hypersensitivity Reactions: Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
- Infections: Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.
- Progressive Multifocal Leukoencephalopathy (PML): PML, a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported. Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms that may include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
- Liver Injury: There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
- Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.
Adverse reactions
The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.
Drug interactions
Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers. Upon initiation or discontinuation of ENTYVIO in patients treated with CYP450 substrates, monitor drug concentrations or other therapeutic parameters, and adjust the dosage of the CYP substrate as needed.
INDICATIONS
Adult Ulcerative Colitis (UC):
ENTYVIO is indicated in adults for the treatment of moderately to severely active UC.
Adult Crohn’s Disease (CD):
ENTYVIO is indicated in adults for the treatment of moderately to severely active CD.
Dosage forms & strengths:
- ENTYVIO Intravenous (IV) Infusion: 300 mg vedolizumab
- ENTYVIO Subcutaneous (SC) Injection: 108 mg vedolizumab
Please click for Full Prescribing Information.
